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   The present study was conducted to confirm the effects and correlations  of estradiol hormone  on  
some major clotting factors (fibrinogen FI , prothrombin FII,  stable factor F VII,  antihemophilic factor 
FVIII,  and chrismas factor IX) during pregnancy phases.  Seventy five (75) pregnant women at 
different stages of pregnancy and were sub- divided into third groups according to period of  
gestational phases , included twenty five (25) pregnant women in each group (first, second, third 
trimesters). Twenty (20) volunteer  non-pregnant non-lactating women were involved in this study and 
used as a control group. All ages of tested  women ( pregnant and non- pregnant) were between 25 year  
to 35 year old . Regarding levels of estradiol hormone , they were showed insignificant elevation 
(p>0.05) during first trimester and remarkable increase (p< 0.05) during second and third trimesters 
when matched with their counterparts of non- pregnant group. About concentrations of fibrinogen 
factor (FI) , they were indicated a significant heightening (p< 0.05) during all phases of pregnancy in 
matching with control group, and these concentrations have a positive correlation (r =0.714) with levels 
of estradiol.  Activities of prothrombin factor ( F II) were significantly elevated (p<0.05) throughout 
pregnancy phases than of non- pregnant women , and have a significant positive correlation ( r =0. 532) 
with estradiol hormone . Levels of stable factor (F VII ) activity indicated insignificant increase  (p> 
0.05 ) in first and second trimesters and its activities become increased (p< 0.05) at third trimester in a 
comparison with those of control group, and pointed out a significant positive correlation ( r = 0.412 ) 
with estradiol level  .   Estimation of intrinsic pathway activities (antihemophlic factor FVIII and 
Chrismas factor FIX ) were showed a progressive elevation  (p< 0.05) during first, second, and third 
trimesters in a comparison with control group, and these activities confirmed a significant positive 
correlation  (r =0.260 , r =0.632, respectively) with estradiol. 
 
 Key words: pregnancy, estradiol hormone, clotting  factors, bleeding.  
ةصلاخلا 
زيكارت ضعب ىمع لويدارتسلاا نومرى زيكارت تاطابتراو تاريثات ةفرعمل ةيلاحلا ةساردلا تعضو ةسيئرلا رثختلا لماوع تايلاعفو 
( نيجونيربيافلاFI نيبمورثوربلاوFII تباثلا لماعلاوFVII فزنمل داضملا لماعلاوFVIII سامسيرك لماعوFIX . لمحلا لحارم للاخ )
ا ةساردلا تنمضت رابتخ75 ةأرمأ  اقبط عيماجم ثلاث ىلا لماوحلا ءاسنلا تمسق دقو , لمحلا نم ةفمتخم لحارم للاخ لماوحلا نم
 عيماجملا تممش ذا , لمحلا لحارمل15  رما أ رابتخا ةساردلا تممش كلذك . لمحمل ثلاثلاو يناثلاو لولاا روطلا نم ةعومجم لك يف ة
20  رما أةعومجمك تاعضرم ريغو لماوح ريغ ة  نيب ةيلاحلا ةساردلا يف ءاسنلا رامعا عيمج تحوارت.ةرطيس 25  و35  تنيب . ةنس
 يونعم ريغ اعافترا نيجورتسلاا نومرى زيكارت  p<0.05) )  ايونعم اعافترا تطعاو لمحلا نم لولاا روطلا للاخp<0.05) ) للاخ
ةرطيسلا ةعومجم عم ةنراقملا دنع لمحلا نم ثلاثلاو يناثلا روطلاا ريغ ()لماوحل  زيكارت تمجس دقف , رثختلا لماوع صخي اميف اما.
نيجونيربيافلا    ايونعم اعافتراp<0.05) ) ى زيكرت عمنيجورتسلاا نومر  حلا لحارم عيمج يفيباجيا اطابترا هزيكارت تنيبو لم 
هرادقمr=0.714  . لويدارتسلاا نومرى زيكارت عم 
 يونعم عافترا دوجو ظحول(p<0.05) عف ميق يف تريظاو لماوحلا ءاسنلا عيمج يف نيبمورثوربلا لماع تايلا وتايلاعف يباجيا طابترا
هرادقم r=0.523   نيجورتسلاا نومرى زيكرت عم يونعم عافترا دوجو تباثلا لماعلا تايلاعف ميق تريظا .(p<0.05)  روطلا للاخ
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يباجيا طابترا تنيب امك لمحلا نم ثلاثلاو يناثلاو لولااp=0.412  رت عم تايلاعف صوصخب اما . لويدارتسلاا نومرى زيك لماوع
 يونعم عافترا دوجو ظحول دقف ) سامسيرك لماعو فزنمل داضملا لماعلا ( يمخادلا راسملا(p<0.05) اسنلا عيمج يفء   لماوحلا
 يباجيا طابترا تطعاوp=0.632  لويدارتسلاا نومرى ميق عم.                                                                                                               
 ةيحاتفملا تاممكلالمحلا:  ,رثختلا , فزنلا , لويدارتسلاا نومرى                                                 .     
Introduction  
      Many physiological changes and fluctuations in different organs and systems of 
the body occur during pregnancy, these changes are achieved by essential sexual 
hormones of female particularly human chorionic gonadotropin (hCG), progesterone, 
estrogens, follicular stimulating hormone (FSH) ,luteal hormone(LH),human placental 
lactogen(hPL), to perform specific care during pregnancy , one should be complete 
understanding about these fluctuations of these hormones and other physiological 
changes occurring in other parts of the body(Sifakis  and Pharmakides 2000)
 
.Also, 
pregnancy characterized  with several complex of hormones and many interactions 
among hormone and their  activities that lead to large physiological alterations , many 
of these  alterations seem remarkable than that occur in other organs , it is well known 
that these physiological alterations result from elevation of fetal requirements for 
development and preparing different maternal organs responsible for delivery and 
feeding of fetus , one of the most hormonal changes that  appear  more prominent and 
ensure normal pregnancy  are more production of female sexual hormones , 
especially, estrogens and progesterone (Casanueva  et al., 2003).
 
Human and other 
mammalian animals develop specific mechanism to ensure prevent loss of their blood 
by injuries and maintain   fluidity of blood within vascular system , these mechanism 
called hemostasis. Formation of blood clot is more limited to enhance closure of 
wound opening  , and blood clot produced as a result of interaction and synergism 
among different components of blood circulation which include blood vasculature , 
blood platelets ,clotting factors , fibrinolysis . Together ,  hemostasis components  
play a critical role to stop bleeding by formation of clot at injury and prevent disturb 
of blood flow beyond site  wound(Saja ,2009).   
 
Women of the study 
     The present work was performed  in Babylon and Karbala teaching hospitals / Iraq, 
during the period ranged  from January  2016 to  June 2016  .  Seventy five (75) 
women were pregnant and enrolled,  pregnant women were subdivided into three 
subgroups( first group included 25 women at first trimester, second group included 25 
women at second trimester , third group included 25 women at third trimester). 
Twenty  (20) women were non-pregnant and non- lactating  with normal menstrual 
cycle were used a control group.  Ages of women (pregnant and non- pregnant) in this 
study were 25 years to 35 years old  . Including criteria of women were normal 
menstrual cycle , normal pregnancy , timing of trimesters . Excluded criteria involved    
hypertension, diabetes mellitus, bone diseases, thyrotoxicosis, smoking, preeclampsia,  
contraceptive drugs, polycystic ovary, and recurrent  abortion . 
 
Collection of Blood Samples:- 
     The Collection of blood samples from studied women in this study  was performed 
in paternity hospitals in Babylon and Baghdad provinces . Anticupital vein of left arm 
was selected and warmed to improve blood flow and swollen of targeted vein and 
then a elastic tourniquet was applied above the collection site  and skin was sterilized 
with alcohol (70 %). Two groups of labeled tube were selected to collect the blood 
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samples, the first group of tubes contained tri-sodium  citrate as anti-coagulant to 
impair blood coagulation that used for estimation of clotting factor activities .These 
tubes were transferred to centrifuge at 3000xg for at a least 10 minutes, then   plasma 
parts were readily transferred for measurement of clotting factor activities. The 
second group of labeled tubes were without anticoagulant (plain gel tubes) and blood 
samples in these tubes  were left for about 10 minutes to permit blood to clot and then 
transferred  for centrifugation at 2500 xg to obtain the sera for measurement of 
estradiol hormone . 
 
 Determination  of estradiol concentration 
     Enzyme immunoassay was used and its reagents include ( antibodies, conjugation 
of enzyme- antigen and native antigen). The interaction among these components is 
depicted by the following reaction: (according  to commands of Monobind Inc kit). 
  Ag    +    AbBtn   ⇌   AgAbBtn 
 
Estimation of Fibrinogen concentration (Factor I) 
    According to Biolabo Kit based on von clauses  validated by Destining, an excess 
amount  of thrombin factor is present, the pre-diluted plasma clotting time is reverse 
order proportionate to the fibrinogen levels in that sample. (According to Biolabo kit). 
 
Measurement of prothrombin factor(F II )activity 
  The method is based on determination of clotting time of specimen . According 
to kit supplied by Diagnostic Stago that involve   in the presence of the STA- 
Neoplastine reagent, of a system in which all the clotting factors are present in 
excess (supplied by STA–Deficient II) with exception of prothrombin  factor II 
which can be derived from the sample that already tested (According to Diognostica 
Stago kit). 
Determination of Stable factor (F VII) 
     Also ,  the assay is depend on the determination of the clotting time, in the 
presence of Neoplastine reagent of a system that has all the  clotting factors, constant 
and in excess (supplied by STA- deficient VII) except stable factor(F VII) which is 
presented in the sample that prepared for testing (According to Diognostica Stago kit).  
Measurement of factor VIII activity:- 
     The method based on  the estimation of the clotting time, in the presence of 
cephalin and activator .In exception of factor VIII that is released from sample , all 
the other factors are present in excess (Supplied by STA- Dificient VIII) (According 
to Diognostica Stago kit). 
Determination of Factor IX activity:- 
     This assay is involved  the measurement of the clotting time  of blood sample 
according to  presence of cephalin and activator . All clotting factors are present in 
excess (supplied by STA-deficient IX) with exception of Chrismas factor(F IX) 
which can be extracted from the sample preparing to  test  (According to Diognostica 
Stago kit). 
 
Statistical analysis  
     The results of the present study were showed as means ±  stander deviation ( SD). 
All results were completely analyzed by computer program ( SPSS) . To explaind the 
differences among tested groups , the low significant different (LSD) was used and 
p<0.05 were used as a lower significant difference( Daneil, 1999).    




     All results of this study are  illustrated in following  table  and included on the 
results of estradiol concentration , clotting factor activities (FI, FII, FVII, FVIII, FIX) 
Esradio hormone concentration  
    The values of estradiol concentration were insignificantly increased (p>0.05) in 
first group(first trimester) and indicated a remarkable heightening (p<0.05) in both 
second and third groups (second and third trimester) of pregnant women in matching 
with non- pregnant women (control group). 
Levels of fibrinogen concentration (F I) 
         Fibrinogen concentrations are markedly elevated ( p<0.05) in all pregnant 
women ( first , second , and third trimesters) when compared with those non- pregnant 
women. 
Activities of prothrombin factor (F II)     
  Activities of FII are significantly increased (p<0.05) throughout period of pregnancy 
in all pregnant women groups in a comparison with those counterparts of non- 
pregnant women 
Activities of stable factor( FVII ) 
     From data mentioned in below table , the levels of FVII activities were showed an 
insignificant increase (p>0.05) during first and second trimesters and they indicated a 
significant increase (p<0.05) in third trimester when compared with control group .  
Activities  of antihemphilic factor ( FVIII ) :- 
     The activities of FVIII are significantly elevated (p<0.05) in all groups of pregnant 
women in a comparison with those non- pregnant women .  
Activities of Chrismas factor( FIX) activity :- 
     These activities are illustrated in below table and indicated a significant increase 
(p<0.05) in all trimesters of pregnancy of women when matched with those non- 
pregnant women . 
 
Table :- Shows  the means of estradiol concentration (pg / ml ) and clotting 
factors: fibrinogen concentration (FI g/dL), prothrombin factor (FII %), stable 
factor (FVII %), anti haemophilic factor (FVIII %), and chrismas factor (FIX 
%) during  first, second, and third trimesters of pregnancy and non-pregnant 
women (control group). 
Control group  
Third group 
 
Second group  
 
 First group       




 2506.33±634.92* 422.47±144.87 Estradiol concentration 
(pg/mL) 
212.45 ± 18.13 367.18 ± 23.55
*




  FI activities (g/dL) 
113.28± 2.33 136 ± 3.91
*
 129.15 ± 2.86
*
 122.81 ± 2.99
*
  FII activities (%) 
115.78 ±5.23 137± 4.33
*
 124.32 ± 4.82 123.55 ± 3.28 FVII activities (%) 
112.92 ± 4.36 137.59 ±4.67
*
 119.56 ± 3.49
*
 126.39 ± 2.87
*
 FVIII activities (%) 
104.56 ± 8.44 135.24 ± 3.98
*
   120.23 ±6.24
*
 118 ± 6.44
*
 FIX activities (%) 
 
                    - Results illustrated above are means ± stander deviation. 
                    - Means having a mark * are significantly different( p<0.05).  
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Correlations among levels of estrogen hormone and activities of clotting factors 
in pregnant and non- pregnant women  
1. A significant positive correlation (r = 0.714)  is found between FI concentrations 
and estradiol concentration during pregnancy  ( first, second, and third trimesters). 
2. A positive correlation (r=0.532) has been found between FII activities and 
estradiol concentration in pregnant women  
3. A significant positive correlation (r = 0.412) indicated between FVII activities and 
estradiol concentration during pregnancy phases . 
4. A significant positive correlation (r=0.260) is confirmed between estradiol 
concentration and FVIII activities in pregnant women. 
5. A significant  positive correlation (r=0.632) is established between estradiol 




Fig. (1):- Shows  correlation between estradiol hormone (pg/ml) and FI 
concentrations (g/dL) during pregnancy trimesters 
 
Fig. (2) :- Shows correlation between FII (%) activities and estradiol 















Fig. (3):- Shows  correlation between FVII activities ( % ) and estradiol 
concentrations ( pg / ml) during pregnancy trimesters 
 
Fig. (4):- Shows correlation between FVIII activities and estradiol hormone  
( pg / ml) during pregnancy trimesters 
 
 
 Fig. (5) :- Shows correlation between FIX( %) activities and estradiol 











Fibrinogen (FI) concentration 
   In normal pregnancy, bodies of pregnant women have multiple alterations, 
especially in mechanisms responsible for maintaining of hemostatic pathways, many 
physiological changes happen during pregnancy and involved, particularly in 
activities of many clotting factors and these changes are believed as developmental 
pathways of pregnant females to prevent excessive bleeding during labour (Ganchev 
and Ludlam 2004).   Data of this work are consistent with Greer (1994) who indicated 
an increase of fibrinogen concentrations in pregnancy. The present study agrees with 
previous studies study that reported during pregnancy the levels of coagulation factor 
(Fibrinogen) increase significantly (Greer, 1994, Choi and Pai, 2002).  
 
 
    Walker et al. (1994).  showed increase of fibrinogen is started from first stages of 
gestation and progress in double toward final stages of term   .  It is well documented 
that the activities and concentrations of many clotting factors progressively increase 
,fibrinogen ,in particular (Donohoe et al.,2002).
 
Studies also indicated that increase 
fibrinogen clearance with advanced pregnancy ( Roque et al.,2004) and these levels of 
fibrinogen are important to prevent abruption of placenta that increased with progress 
of pregnancy( Kobayashi et al.,2000). 
 
Activities of Factor II  
  Previous work indicated a moderate increase in the activities of FII during pregnancy 
or tend to remain within normal range (Clark etal.,1998). The present data disagree  
with previous study that mentioned prothrombin activity can to increase during first 
stage of pregnancy and return to normal limits at time of labou( Kadir etal.,2009) and 
also it found that in pregnancy phases the activities of FII  tended to elevate during 
early phase  of pregnancy and then return to levels as in non- pregnant women on 
progress of pregnancy (Holmes and Wallace 2005). During pregnancy, there are many  
changes occurring in mechanisms and components of hemostatic system, including 
increase of procoagulants, lowering of anticoagulants,and depressed fibrinolysis, 
these changes render prothrombotic events are more occurring(Connors, 2011). It is 
well founded that thrombin production mechanism become increased in particular in 




Activities of  FVII 
     These data are appeared to agree with previous studies which confirmed that stable 
factor activity gradually increase when pregnancy become progressed, and also 
another studies showed a progress heightening of FVII activity within gestational 
phases (Donohoe et al., 2002; Choi and Pai ,2002; Hellgren, 2003).  It is found that a 
marked  increase in FVII concentrations during third trimester( Kadir et al.,2009).  A 
remarkable rise in many clotting factors is related with pregnancy , FVII in particular 
(Uchkova and Ledjev  2005).  Increase FVII activity  has more importance to impair 
threatened abortion( Kadir etal.,2009).  Levels of many  clotting factors , including 
FVII, FXIIa, and vWF are found to rise in blood of pregnant women and have been 
shown to be higher in maternal plasma and associated with impairment to intrinsic 
production of anticoagulant including APC Wickstrom et al.,2004; Peek et al., 1997).  
 
Activities of FVIII 
       The present data are consistent with previous research which pointed out an 
elevation the clotting factor (FVIII) at all phases of pregnancy (Ganchev and Ludlam 
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2004). More ever, other previous studies  of Oriodran and Higgins (2003); Thornton 
and Douglas (2010) are also consistent with present data and  indicated an increase of  
FVIII in pregnant women. There is a higher elevation in the levels factor VIII 
concentrations  and its clotting activity at trimesters of pregnancy (Clark et al.,1998; 
Blomback, 1991; Kjellberg et al.,1999). 
 
Also, There is a double increase of FVIII in 
particular at third trimester in comparison with that of first trimester and these 
changes explain an evolutionary process in pregnant females to increase defense 
mechanisms against excess bleeding at labour( Prisco et al.,2005).  
  
 Activities of FIX 
  There is found the elevation of FIX concentrations and efficiency of intrinsic 
pathways during trimesters are at a lower level ( Prisco et al.,2005).  Study of Clark et 
al., (1998) showed there is a moderate increase or remain at normal limit of FIX 
during pregnancy. The present results obtained from this study appear  consistent with 
study of  Donohoe et al., (2009) which confirmed that activity of stable factor(FIX) 
become progressively increased during gestation. Also, a study of Greer (1998) which 
indicated that there is an elevation of FIX in trimesters. According to physiological 
principals, There are several changes occuring during pregnancy and associated with 
various hemostatic mechanisms that are necessary to increase defense mechanisms to 
prevent excessive bleeding  and to keep normal functions, parts of these changes 
involve increase clotting activities and decrease fibrinolysis to ensure 
hypercoagulability states that are essential to stop of bleeding at expulsion of placenta 
(Prisco et al.,2005; Riddle et al.,2007).    
 
Conclusion 
The possible explanation of these data can be return to physiological facts that 
explain   increased activities and concentrations of different clotting factors involved 
in clotting pathways that continue with progress of pregnancy, and these activities 
may be resulted because of a higher levels of estradiol hormone that may be exerted a 
stimulatory effect to enhance concentrations and activities of different clotting factors 
to ensure a defense role that prevent excessive blood loss during parturition .  
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